PPCB Stock Overview
A biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Propanc Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00025 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.0002 |
| Beta | 1.91 |
| 11 Month Change | -16.67% |
| 3 Month Change | -37.50% |
| 1 Year Change | -96.97% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PPCB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.7% | 2.4% | 0.5% |
| 1Y | -97.0% | 15.6% | 30.7% |
Return vs Industry: PPCB underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: PPCB underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| PPCB volatility | |
|---|---|
| PPCB Average Weekly Movement | 34.6% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PPCB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PPCB's weekly volatility has decreased from 43% to 35% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2 | James Nathanielsz | www.propanc.com |
Propanc Biopharma, Inc., a biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research collaboration with University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation; and a joint research and drug discovery program with Universities of Jaén and Granada for the POP1 program to investigate the changes in genetic and protein expression that occur in cancer cells.
Propanc Biopharma, Inc. Fundamentals Summary
| PPCB fundamental statistics | |
|---|---|
| Market cap | US$197.47k |
| Earnings (TTM) | -US$1.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PPCB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PPCB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.87m |
| Earnings | -US$1.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -26.5% |
How did PPCB perform over the long term?
See historical performance and comparison